Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Validity Threats in Preclinical Studies of New Cancer Drugs: A Systematic Analysis

EF 2013-14

Résumé
Clinical translation is an onerous and time-consuming process that is burdened by high attrition rates, the highest of which are observed in cancer drug translation. These failures are of a major concern to health research and policy as they expose patients to harmful and ineffective treatments and waste human and financial resources. Since clinical development is largely justified by studies of preclinical efficacy in animals, the attrition problem is increasingly being linked to methodological flaws in the conduct of these studies. Commentators have suggested that decision-makers focus on reporting methodological features in preclinical studies that address such threats to valid clinical inference. This project proposes a systematic analysis of the relationship between design and outcomes of in vivo animal efficacy trials and Phase 2 trial outcomes in a cohort of both licensed and unlicensed cancer drugs, following their progression from preclinical to clinical stages. Our approach will be to complete a systematic review and meta-analysis of the designs and outcomes of both preclinical and clinical trials for a cohort of cancer drugs that first appeared in the clinical literature between 2000 and 2003. In particular, this project will examine the extent to which these preclinical studies address threats to valid clinical inference and identify predictors for successful clinical translation. In this way, we hope to further our understanding of the science of translation, honing in on the risk and benefit assessments and knowledge gains at preclinical stages of the development trajectory. Ultimately, we aim to provide evidence for improving the conduct and reporting of preclinical cancer studies in order to encourage ethical policies and decision-making.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311681
Name
Demko Nadine E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Validity Threats in Preclinical Studies of New Cancer Drugs: A Systematic Analysis
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Research Design; Drug Research And Design; Knowledge Translation; Preclinical Conduct And Reporting Guidelines; Quality Improvement; Research Validity; Systematic Reviews
Abstract
Clinical translation is an onerous and time-consuming process that is burdened by high attrition rates, the highest of which are observed in cancer drug translation. These failures are of a major concern to health research and policy as they expose patients to harmful and ineffective treatments and waste human and financial resources. Since clinical development is largely justified by studies of preclinical efficacy in animals, the attrition problem is increasingly being linked to methodological flaws in the conduct of these studies. Commentators have suggested that decision-makers focus on reporting methodological features in preclinical studies that address such threats to valid clinical inference. This project proposes a systematic analysis of the relationship between design and outcomes of in vivo animal efficacy trials and Phase 2 trial outcomes in a cohort of both licensed and unlicensed cancer drugs, following their progression from preclinical to clinical stages. Our approach will be to complete a systematic review and meta-analysis of the designs and outcomes of both preclinical and clinical trials for a cohort of cancer drugs that first appeared in the clinical literature between 2000 and 2003. In particular, this project will examine the extent to which these preclinical studies address threats to valid clinical inference and identify predictors for successful clinical translation. In this way, we hope to further our understanding of the science of translation, honing in on the risk and benefit assessments and knowledge gains at preclinical stages of the development trajectory. Ultimately, we aim to provide evidence for improving the conduct and reporting of preclinical cancer studies in order to encourage ethical policies and decision-making.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Demko, Nadine E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~